Hledání článků
Filtry
EMPA‑KIDNEY Collaborative Group, Herrington WG, Staplin N, et al. Long‑term effects of empagliflozin in patients with chronic kidney disease. N Engl J Med 2024, Oct 25, doi:10.1056/NEJMoa2409183. Online ahead of print.
Heerspink HJL, Jardine M, Kohan DE, et al. Atrasentan in Patients with IgA Nephropathy. N Engl J Med Oct 25 2024; doi: 10.1056/NEJMoa2409415. Online ahead of print.
Heerspink HJL, Cherney D, Gafor AHA, et al. Effect of Avenciguat on Albuminuria in Patients with CKD: Two Randomized Placebo‑Controlled Trials. J Am Soc Nephrol 2024;35:1227–1239.
Chan EY, Sinha A, Yu ELM, et al. An international, multi‑center study evaluated rituximab therapy in childhood steroid‑resistant nephrotic syndrome. Kidney Int 2024;106:1146–1157.
Anderegg MA, Olinger EG, Bargagli M, et al. Prevalence and characteristics of genetic disease in adult kidney stone formers. Nephrol Dial Transplant 2024;39:1426–1441.
Chaturvedy M, Maurya SK, Bajpai NK, et al. Relationship between biochemical parameters of mineral bone disease and static bone histomorphometry in chronic kidney disease patients on hemodialysis: An Indian cross‑section study. Nefrologia (Engl Ed) 2023;43(Supl 2):67–76.
Theodorskopoulou M, Ortis A, Fernandez Fernandez B, et al. Guidelines for the management of hypertension in CKD patients: where do we stand in 2024?
Clin Kidney J 2024;17(Suppl 2):ii36–ii50.
Kaufeld JK, Kühne L, Schönermarck U, et al. Features of postpartum hemorrhage‑associated thrombotic microangiopathy and role of short‑term complement inhibition. Kidney Int Rep 2024;9:919–928.
Perkovic V, Tuttle KR, Rossing P, et al. Effect of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 2024;391:109–121.
Bada‑Bosch T, Sevillano AM, Sanchez‑Calvin MT, et al. Cystic phenotype and chronic kidney disease in autosomal dominant Alport syndrome. Nephrol Dial Transplant 2024;39:1288–1298.